Question explored with the scientific record
How to treat UC
UC is treatable, but the drug evidence is mostly short trials of symptoms, not long-term proof of fewer surgeries or deaths.
Where you start depends on how bad the flare is. For mild-to-moderate disease, especially proctitis (rectum only), topical 5-ASA works: about 65 in 100 reached remission versus 25 in 100 on placebo [3]. For acute severe disease, IV steroids are standard, and about 67 in 100 respond [6]. If day-3 stool counts or CRP flag steroid failure, rescue with infliximab or cyclosporine is the consensus next step [6].
The newer drugs post big symptom numbers, but read the design. Upadacitinib hit 83 in 100 remission at week 8 versus 7 in 100 on placebo [1], and filgotinib showed 37 in 100 at week 52 versus 11 in 100 [4]. These are industry-run trials using symptom scores, not hard outcomes like colectomy or death. The one hard-outcome signal is mixed: a meta-analysis found infliximab cut surgery odds [5], but a single-center cohort found rising biologic use with no change in surgery rates [5].
| Drug | Remission vs placebo | Notes |
|---|---|---|
| Topical 5-ASA (proctitis) | 65% vs 25% [3] | Cheapest, safest first step |
| Upadacitinib 45mg (wk 8) | 83% vs 7% [1] | JAK inhibitor; zoster risk [1] |
| Filgotinib 200mg (wk 58) | 37% vs 11% [4] | Industry trial, symptom endpoint |
| Vedolizumab (wk 52) | 42% vs 16% [2] | Gut-selective, no PML seen [2] |
The safety data is thin. JAK inhibitors carry shingles and malignancy signals [1], tacrolimus caused kidney decline in about 36 in 100 [8], and thiopurines caused adverse events in about 22 in 100 [7]. No retrieved trial compares treated patients to a genuinely untreated group over years.
My call: start with 5-ASA and steroids for flares, reserve biologics and JAK inhibitors for steroid-refractory disease, and demand hard-outcome data before committing to lifelong immunosuppression. Confidence: moderate on acute management, low on long-term drug superiority.
Sources used 8
-
Selective JAK1 inhibition using upadacitinib for the management of inflammatory bowel diseases
Upadacitinib, a selective JAK1 inhibitor, is reviewed for its mechanism and phase 3 clinical efficacy in inducing and maintaining remission in ulcerative colitis and Crohn's disease, with safety considerations and practical implications.
DOI: 10.58931/cibdt.2023.1s1121 -
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn’s disease
Vedolizumab induces clinically meaningful induction and durable maintenance of remission in moderate-to-severe ulcerative colitis and Crohn's disease, with superior clinical response, remission, and mucosal healing versus placebo in GEMINI trials, a gut-selective mechanism with …
DOI: 10.1177/2040622315586970 -
Drug Therapies for Ulcerative Proctitis
This systematic review and meta-analysis evaluates the efficacy of drug therapies, particularly topical 5-aminosalicylic acid (5-ASA), for inducing and maintaining remission in patients with ulcerative proctitis, finding that 5-ASA is significantly more effective than placebo.
DOI: 10.1097/MIB.0000000000000141 -
Efficacy and safety of filgotinib in the treatment of ulcerative colitis with a focus on rapid and sustained efficacy: a narrative review
This narrative review synthesizes data from the SELECTION and SELECTIONLTE trials and real-world studies to evaluate the efficacy and safety of filgotinib for ulcerative colitis, highlighting rapid onset of symptom relief, durable long-term remission and quality-of-life gains, a…
DOI: 10.5217/ir.2025.00155 -
Complications and surgery in the inflammatory bowel diseases biological era
Although anti-TNF agents are effective short term, their ability to prevent complications and surgery in inflammatory bowel disease remains unclear and observational data conflict.
DOI: 10.1097/mog.0000000000000078 -
Review article: acute severe ulcerative colitis – evidence‐based consensus statements
An Australian multidisciplinary consensus recommends hospitalisation, unprepared flexible sigmoidoscopy, venous thromboembolism prophylaxis, intravenous hydrocortisone, and early rescue therapy with infliximab or ciclosporin for acute severe ulcerative colitis to reduce colectom…
DOI: 10.1111/apt.13670 -
Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
Thiopurine maintenance therapy sustains long-term remission in steroid-dependent/refractory ulcerative colitis.
DOI: 10.1093/crocol/otab003 -
Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis
Long-term tacrolimus therapy may maintain remission in ulcerative colitis but increases risk of nephrotoxicity requiring regular renal monitoring.
DOI: 10.3390/jcm9061771